Enhanced expression of complement and microglial-specific genes prior to clinical progression in the MOG-experimental autoimmune encephalomyelitis model of multiple sclerosis

Baker, 2020, Autoimmune encephalomyelitis in NOD mice is not initially a progressive multiple sclerosis model, Ann. Clin. Transl. Neurol. Brown, 2019, Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis, JAMA, 321, 175, 10.1001/jama.2018.20588 D’Amico, 2016, Negative prognostic impact of MRI spinal lesions in the early stages of relapsing-remitting multiple sclerosis, Mult. Scler. J. Exp. Transl. Clin., 2 DePaula-Silva, 2019, Differential transcriptional profiles identify microglial- and macrophage-specific gene markers expressed during virus-induced neuroinflammation, J. Neuroinflammation, 16, 152, 10.1186/s12974-019-1545-x Dubbelaar, 2018, The kaleidoscope of microglial phenotypes, Front. Immunol., 9, 1753, 10.3389/fimmu.2018.01753 Fonseca, 2017, Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain, J. Neuroinflammation, 14, 48, 10.1186/s12974-017-0814-9 Geiss, 2008, Direct multiplexed measurement of gene expression with color-coded probe pairs, Nat. Biotechnol., 26, 317, 10.1038/nbt1385 Greene, 2019, Claudin-5: gatekeeper of neurological function, Fluids Barriers CNS, 16, 3, 10.1186/s12987-019-0123-z Hammond, 2019, Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes, Immunity, 50, 253, 10.1016/j.immuni.2018.11.004 Hammond, 2020, Complement-dependent synapse loss and microgliosis in a mouse model of multiple sclerosis, Brain Behav. Immun., 87, 739, 10.1016/j.bbi.2020.03.004 Hampton, 2008, An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss, J. Neuroimmunol., 201-202, 200, 10.1016/j.jneuroim.2008.05.034 Huang, 2007, DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists, Nucleic Acids Res., 35, W169, 10.1093/nar/gkm415 Ingle, 2003, Primary progressive multiple sclerosis: a 5-year clinical and MR study, Brain, 126, 2528, 10.1093/brain/awg261 Ingram, 2014, Complement activation in multiple sclerosis plaques: an immunohistochemical analysis, Acta Neuropathol. Commun., 2, 53, 10.1186/2051-5960-2-53 Jordao, 2019, Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation, Science, 363, 10.1126/science.aat7554 Kappos, 2018, Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study, Lancet, 391, 1263, 10.1016/S0140-6736(18)30475-6 Kearney, 2015, Cervical cord lesion load is associated with disability independently from atrophy in MS, Neurology, 84, 367, 10.1212/WNL.0000000000001186 Keren-Shaul, 2017, A unique microglia type associated with restricting development of alzheimer’s disease, Cell, 169, 1276, 10.1016/j.cell.2017.05.018 Koch, 2010, The natural history of secondary progressive multiple sclerosis, J Neurol Neurosurg Psychiatry, 81, 1039, 10.1136/jnnp.2010.208173 Krasemann, 2017, The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases, Immunity, 47, 566, 10.1016/j.immuni.2017.08.008 Kuhlmann, 2002, Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time, Brain, 125, 2202, 10.1093/brain/awf235 Kutzelnigg, 2005, Cortical demyelination and diffuse white matter injury in multiple sclerosis, Brain, 128, 2705, 10.1093/brain/awh641 Lassmann, 2018, Pathogenic mechanisms associated with different clinical courses of multiple sclerosis, Front. Immunol., 9, 3116, 10.3389/fimmu.2018.03116 Lepore, 2018, CXCL16/CXCR6 Axis Drives Microglia/Macrophages phenotype in physiological conditions and plays a crucial role in glioma, Front. Immunol., 9, 2750, 10.3389/fimmu.2018.02750 Levy, 2010, Characterization of brain lesions in a mouse model of progressive multiple sclerosis, Exp. Neurol., 226, 148, 10.1016/j.expneurol.2010.08.017 Love, 2014, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol., 15, 550, 10.1186/s13059-014-0550-8 Lynch, 2004, Microglial activation and increased synthesis of complement component C1q precedes blood-brain barrier dysfunction in rats, Mol. Immunol., 40, 709, 10.1016/j.molimm.2003.08.009 Mangiardi, 2011, An animal model of cortical and callosal pathology in multiple sclerosis, Brain Pathol., 21, 263, 10.1111/j.1750-3639.2010.00444.x Masuda, 2019, Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution, Nature, 566, 388, 10.1038/s41586-019-0924-x Masuda, 2020, Microglia heterogeneity in the single-cell era, Cell Rep., 30, 1271, 10.1016/j.celrep.2020.01.010 Michailidou, 2015, Complement C1q-C3-associated synaptic changes in multiple sclerosis hippocampus, Ann. Neurol., 77, 1007, 10.1002/ana.24398 Mildner, 2009, CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system, Brain, 132, 2487, 10.1093/brain/awp144 Montalban, 2017, Ocrelizumab versus placebo in primary progressive multiple sclerosis, N. Engl. J. Med., 376, 209, 10.1056/NEJMoa1606468 Neil, 2017, Oral administration of the nitroxide radical TEMPOL exhibits immunomodulatory and therapeutic properties in multiple sclerosis models, Brain Behav. Immun., 62, 332, 10.1016/j.bbi.2017.02.018 Peterson, 2001, Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions, Ann. Neurol., 50, 389, 10.1002/ana.1123 Sacca, 2019, Determinants of therapy switch in multiple sclerosis treatment-naive patients: a real-life study, Mult. Scler., 25, 1263, 10.1177/1352458518790390 Torkildsen, 2016, Disease-modifying treatments for multiple sclerosis - a review of approved medications, Eur. J. Neurol., 23, 18, 10.1111/ene.12883 Trapp, 1998, Axonal transection in the lesions of multiple sclerosis, N. Engl. J. Med., 338, 278, 10.1056/NEJM199801293380502 Vilarino-Guell, 2019, Exome sequencing in multiple sclerosis families identifies 12 candidate genes and nominates biological pathways for the genesis of disease, PLoS Genet., 15, 10.1371/journal.pgen.1008180 Watkins, 2016, Complement is activated in progressive multiple sclerosis cortical grey matter lesions, J. Neuroinflammation, 13, 161, 10.1186/s12974-016-0611-x